company background image

Geron NasdaqGS:GERN Stock Report

Last Price


Market Cap







14 Aug, 2022


Company Financials +
GERN fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health5/6

GERN Stock Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.

Geron Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Geron
Historical stock prices
Current Share PriceUS$2.35
52 Week HighUS$2.67
52 Week LowUS$0.99
1 Month Change29.12%
3 Month Change66.67%
1 Year Change92.62%
3 Year Change66.67%
5 Year Change15.76%
Change since IPO-69.68%

Recent News & Updates

Aug 12

Geron rises on narrower-than-expected Q2 loss

Geron (NASDAQ:GERN) is trading ~6% higher after the company posted narrower-than-expected quarterly loss. The company's Q2 GAAP EPS of -$0.07 beat estimates by $0.02. Total operating expenses for the three months were $28M, compared to $29M, a year earlier. Research and development expenses were $20.6M, compared to $21.9M, primarily reflects the net result of decreased manufacturing costs due to the timing of imetelstat manufacturing batches. Revenue fell 30% Y/Y to $0.07M, and missed by $0.04M.

Aug 05
Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Jul 15

Geron: Waiting For Godot

Today, we revisit a small biopharma called Geron for the first time since early in 2021. The company is advancing its lead drug candidate in two key indication, with hopefully its first marketing application to be filed in the first half of 2023. An investment analysis follows in the paragraphs below. "Time​ is​ only​ relative when​ you're​ man." - Anthony T. Hincks It has been nearly a year and a half since we last took a look at a small biotech concern called Geron (GERN). I have been following this story for nearly a decade. The company's quest to achieve FDA approval has been akin to the classical Broadway play 'Waiting for Godot' for some time now. The shares recently hit a 52-week-high. Given that, it seems a good time to circle back on Geron. An analysis follows below. Seeking Alpha Company Overview: Geron is located in San Francisco and is focused on the development and commercialization of therapeutics for hematologic myeloid malignancies. Its primary drug candidate and asset is imetelstat which it has wholly own rights to. Imetelstat is a telomerase inhibitor which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The stock trades just under two bucks a share and sports an approximate market capitalization of $725 million. Recent Developments/Coming Potential Catalysts: Currently, imetelstat is being evaluated in a confirmatory Phase 3 study named IMerge to treat low-risk myelodysplastic syndrome or LR-MDS. Topline data from this trial should be out late in the first quarter of next year. If the results are successful, marketing applications should soon follow. This follows a successful mid-stage study around this indication. May Company Presentation LR-MDS is an affliction that is characterized mainly by anemia in most cases. Supportive care - primarily red blood cell transfusions - remains an important component of their treatment. However, this exposes patients to insufficient correction of anemia, alloimmunization, and organ iron overload. There are just over 30,000 individuals in the U.S. and Europe with this condition, equating to just over a $1 billion annual market in the U.S. and Europe. May Company Presentation In addition, an interim analysis from a Phase 3 study IMpactMF using imetelstat to treat refractory myelofibrosis should be out sometime in 2024 as the company continues to open sites to enroll patients for this trial. Myelofibrosis is a chronic blood cancer in which abnormal or malignant precursor cells in the bone marrow proliferate rapidly, causing scar tissue, or fibrosis, to form. An earlier stage study with 96 patients with Janus kinase (JAK) inhibitor-relapsed/refractory intermediate-2 or high-risk myelofibrosis demonstrated encouraging results with median overall survival of 29.9 months compared to 12 months with the best available therapy ((BAT)). May Company Presentation The company also has several earlier-stage studies around imetelstat in the works. May Company Presentation A month ago, the company announced a new Chief Medical Officer, who has been involved in shepherding imetelstat's development for some time and has played a strategic role in designing and driving execution of the Phase 3 clinical trials around this compound. Analyst Commentary & Balance Sheet: The company gets relatively sparse coverage on Wall Street. On May 11th, Robert W. Baird reissued their Buy rating and $4.00 price target. Both Needham and H.C. Wainwright have reiterated Buy ratings and identical $2.00 a share price targets. Nearly eight percent of the outstanding float in Geron is currently held short. There has been no insider activity in the shares in nearly two years. The company ended the first quarter with approximately $178 million in cash and marketable securities on its balance sheet. Geron then did a secondary offering in April, which raised approximately $75 million. It was a costly capital raise as each share sold had a warrant attached that could be exercised at $1.45 per share. Management has stated that this funding is 'sufficient to fund Geron's projected level of operations, which includes preparatory activities for potential U.S. commercial launch of imetelstat in lower risk MDS, until the end of 2023' Verdict: May Company Presentation Geron, as it always does, has potential. The company believes if imetelstat is approved for its two lead indications, the drug compound could have $3 billion of peak sales potential by FY2023. This is more than four times its current market cap in comparison.

Shareholder Returns

GERNUS BiotechsUS Market

Return vs Industry: GERN exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: GERN exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is GERN's price volatile compared to industry and market?
GERN volatility
GERN Average Weekly Movement11.9%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: GERN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: GERN's weekly volatility (12%) has been stable over the past year.

About the Company

199071Chip Scarlett

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation Fundamentals Summary

How do Geron's earnings and revenue compare to its market cap?
GERN fundamental statistics
Market CapUS$887.87m
Earnings (TTM)-US$116.93m
Revenue (TTM)US$1.35m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GERN income statement (TTM)
Cost of RevenueUS$3.60m
Gross Profit-US$2.25m
Other ExpensesUS$114.68m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.31
Gross Margin-167.43%
Net Profit Margin-8,693.61%
Debt/Equity Ratio35.5%

How did GERN perform over the long term?

See historical performance and comparison